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Abstract 
Purpose: To evaluate the neuroprotective effects of corilagin in cerebral ischaemia-induced cerebral 
injury in a rat model.  
Methods: Cerebral ischaemia was induced by middle cerebral artery occlusion (MCAO). The animals 
were separated into five groups, including a control group that underwent surgery without inserting a 
monofilament; MCAO group that received saline; corilagin-treated group (20 mg/kg corilagin, 
intraperitoneally for 7 days after reperfusion); Tat-Beclin-1-treated group (intraperitoneal injection of 
1.5mg/kg of Tat-Beclin-1 on the 3rd and 6th days after MCAO); and corilagin + Tat-Beclin-1-treated 
group (corilagin for 7 days and Tat-Beclin-1 on the 3rd and 6th days after MCAO). At the end of the 
treatments, neurological deficit, brain oedema, and volume of infarct were determined in all the animals. 
Moreover, the level of autophagy in infarcted tissues was evaluated by immunofluorescence, real-time 
PCR, and western blotting.  
Results: There was a significant decrease in neurological deficit, brain oedema, and volume of 
infarcted tissue in corilagin-treated group when compared with MCAO- and Tat-Beclin-1-treated groups. 
Treatment with corilagin attenuated the autophagy of astrocytes and neurons in cerebral infarcted 
tissue, as demonstrated by immunofluorescence, quantitative PCR, and western blotting data.  
Conclusion: Corlagin has a protective effect against neuronal damage in cerebral ischaemic rats by 
decreasing neurological deficit score, infarct volume, and water content of cerebral tissue. Corlagin 
attenuates autophagy in cerebral tissue, thus protecting cerebral ischaemic rats from neuronal damage. 
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 Cerebral ischaemia induced stroke is the third 
leading cause of mortality and morbidity 
throughout the world. Within a few minutes after 
a stroke with cerebral ischaemia, necrosis occurs 
in cells, and within a few hours to days post-
insult, neurons of the surrounding regions 
undergo injury [1].  Hence, for the prevention of 
neuronal damage, treatment is required within 
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this period of time. Neuronal damage during 
cerebral ischaemia occurs due to activation of 
several mechanisms including autophagy, 
necrosis, and apoptosis [2].  
 
The induction of inflammation and oxidative 
stress activate the apoptotic processes, and 
thereby damages neurons [3]. Oxidative stress 
reduces the synthesis of ATP, thereby disrupting 
mitochondrial functions, which then alters 
calcium concentrations in the brain tissue and 
results in the degeneration of neurons [4]. 
Moreover, during autophagy, the surviving cells 
become depleted of cellular components, which 
results in self-digestion of the damaged cells.  
 
Autophagy is a protective mechanism for cells 
against starvation, stress, and ischaemia [5]. 
Although autophagic activity is required for 
neuroprotection, cell death may occur with 
excessive autophagy. Studies have shown that 
during cerebral ischaemia, apoptosis and 
autophagy were simultaneously activated [6]. A 
study found that apoptosis was activated in 
cerebral ischaemia due to autophagy through the 
upregulation of Beclin-1 [7]. Treatment with 
appropriate drugs protected the autophagic cells, 
thus suggesting that targeting autophagic cells 
could be a good choice for the effective 
management of stroke [8,9]. 
 
In recent years, alternative medicines such as 
herbal medicines have shown potential to 
prevent neuronal damage against cerebral 
ischaemia. Caesalpinia coriaria is traditionally 
used as an herbal medicine in China. An 
ellagitannin isolated from C. coriaria, known as 
corilagin, was reported to possess analgesic, 
hepato-protective, anti-inflammatory, antitumor, 
and antioxidant activities [10-12]. It was reported 
that corilagin possessed analgesic activity by 
altering the glutaminergic system and anti-
inflammatory activity by decreasing the 
production of pro-inflammatory cytokines and 
mediators, TNF-α, IL-1β, IL-6, NO (iNOS), and 
COX-2 at both the protein and gene levels, by 
blocking NF-κB nuclear translocation [13-16]. 
Thus, the present study evaluated the 







Sprague-Dawley rats (200 to 250 g) were used in 
this study. All the rats were housed under a 
controlled condition specified as per the 
guidelines. The animal experiments were 
approved by the institutional animal ethical 
committee of Xianning Central Hospital, The First 
Affiliated Hospital of Hubei University of Science 
and Technology, China (no. AHHU/IAEC/ 
2016/11) and the given study followed the 
guidelines of Association for the Assessment and 
Accreditation of Laboratory Animal Care 
International (AAALAC) for experimentation and 
animal use [17]. 
 
Induction of cerebral ischaemia 
 
All animals were anaesthetised by intraperitoneal 
(i.p.) injection of 10 % chloral hydrate (360 
mg/kg). Later, the internal carotid artery (ICA), 
external carotid artery (ECA), and common 
carotid artery (CCA) were separated from other 
nerves and muscles. An incision was made on 
the ECA, and a 0.36 mm diameter round 
polylysine coated tip, on a 4-0 nylon 
monofilament, was inserted into the ECA to 
model cerebral arterial ischaemia. The 
parameters measured included heart rate, 
arterial blood gases, and blood pressure 
observed during the period of surgery. After 90 
min of middle cerebral artery occlusion (MCAO), 
reperfusion was initiated by withdrawing the 
nylon monofilament. Thereafter, all the animals 
were separated into five groups including a 
control group that underwent surgery without 
inserting a monofilament, a MCAO group that 
received saline, a corilagin-treated group that 
received corilagin at 20 mg/kg, i.p., for the 7 days 
after reperfusion, a Tat-Beclin-1-treated group 
that received i.p. injections of 1.5 mg/kg of Tat-
Beclin-1 on the 3rd and 6th days after MCAO, and 
a corilagin + Tat-Beclin-1-treated group that 
received corilagin for 7 days and Tat-Beclin-1 on 
the 3rd and 6th days after MCAO. 
 
Assessment of functional deficiency of 
neurons 
 
The functional deficiency of neurons was 
assessed after the treatment period by 
estimating the neurological deficit score. 
Neurological deficit scores were determined by 
observing different behaviours, and scoring was 
done as follows: 0, no deficiency of neurological 
function; 1, appearance of flexion in the forelimb; 
2, failure to extend the right forelimb completely 
and the strength to resist a lateral push was 
obviously decreased; 3, forelimb flexion, rotating, 
and crawling towards the right side were 
impaired; and 4, unable or difficult to ambulate 
spontaneously. 
 
Determination of volume of brain infarct 
 
All animals were sacrificed by cervical dislocation 
and the brains were removed and sectioned into 
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2 mm sections. To stain the tissue sections, 0.5 
% triphenyltetrazolium chloride (TTC) solution 
was used for 30 min at 37 oC. Thereafter, to fix 
the tissue sections, paraformaldehyde buffer (4 
%) was used at room temperature for 12 h. TCC 
staining was done to assess the infarcted brain 
tissue areas. A red colour was shown as 
unstained tissues, and a pale colour indicated 
infarcted brain tissues. Imaging software was 
used to determine the volume of the infarct. 
 
Determination of water content of the brain 
 
Cerebral oedema was determined by comparing 
the wet weight with the dry weight of the tissue, 
thereby assessing tissue water content. All 
animals were sacrificed and brains were isolated. 
Immediately after isolation, the weights of the wet 
brain tissues were determined, and thereafter, 
the dry weights of the brain tissues were 
determined after drying the brain samples at 105 
oC in an oven, for overnight. 
 
Western blot assay 
 
The infarct penumbra and tissues of its 
corresponding areas were separated from the 
isolated brain on ice. RIPA buffer that contained 
150 mM NaCl, 1 % sodium deoxycholate, 50 mM 
Tris buffer, 0.1 % SDS, and Triton X 100 (1 %) 
was used to homogenize the tissue at 4°C for 45 
min. The tissue homogenate was centrifuge at 
13,000 RPM at 4 °C for 15 min, and the 
supernatant solution was separated. SDS-PAGE 
was used for the separation of proteins, after 
which samples were transferred to polyvinylidene 
fluoride (PVDF) membranes. Monoclonal rabbit 
antibodies against rat LC3 were used to label the 
tissue proteins, and thereafter, samples were 
rinsed with phosphate-buffered saline (PBS) 
solution with the detergent Tween® 20 (PBST). 
Horseradish peroxidase (HRP)-conjugated anti-
rabbit IgG was used for the PVDF membranes, 
at room temperature for 60 min. After rinsing with 
PBST for 120 min, the reaction was visualized 
with enhanced-chemiluminescence (ECL) 
reagent. 
 
Determination of LC3 mRNA levels 
 
TRIzol® reagent was used to extract total RNA 
from the ischaemic penumbra tissue 
homogenates. As per the manufacturers’ 
guidelines, 1 mg of total RNA was used to 
synthesize the first-strand of complementary 
DNA (cDNA). Primers and SYBR Green I were 
used to perform real time PCR. Amplification of 
PCR products was done using a 20 mL reaction 
and the Mastercycler®1 ep Realplex system 




Sucrose solution (20 %) was used to dehydrate 
the isolated brains overnight, after which 20 mm 
thick sections of brain tissues were sectioned 
using a microtome. A PBS solution was used to 
rinse the tissue sections for 15 min at room 
temperature, and thereafter, 10 % goat serum 
was used to block the tissue sections for 40 min. 
Tissue sections were labelled at room 
temperature for 4 h with mouse antibody against 
rat glial fibrillary acidic protein (GFAP), NeuN, 
and monoclonal rabbit antibodies against rat 
LC3, plus a PBS control. After rinsing, Dylight® 
488-conjugated anti-mouse IgG and Alexa Fluor 
594-conjugated anti-rabbit IgG were incubated 
with tissue sections for 120 min. To stain nuclei, 
6-diamidino-2-phenylindole (DAPI) stain was 
used for 5 min, and observed by fluorescence 
microscopy. 
 
Statistical analysis  
 
All data are shown as mean ± standard deviation 
(SD, n = 10), and were analysed by one-way 
ANOVA, followed by Dunnett’s post hoc test 
(Gradpad prism 6.1., CA, USA). P < 0.05 was 




Effects of corilagin on neurological defects  
 
The effects of corilagin on rat neurological 
defects induced by MCAO in cerebral ischaemia 
are shown in Figure 1. Cerebral ischaemia 
significantly (p < 0.01) enhanced the neurological 
deficit score in the MCAO- and Tat-Beclin-1-
treated groups compared to the control group. 
However, treatment with corilagin significantly 
decreased the neurological deficit score (p < 
0.05, p < 0.01) in cerebral ischemic rats 
compared to the MCAO group. Moreover, the 
neurological deficit scores were increased in the 
corilagin+tat-Beclin-1-treated group compared to 
the corilagin-treated group. 
 
Effect of corilagin on infarct volume 
 
The effect of corilagin on the infarct volume was 
determined by TTC staining as shown in Figure 
2. Treatment with corilagin decreased the size of 
infarcted tissue compared to that of the MCAO 
group. There was a significant increase in the 
volume of infarcted tissue in the MCAO and Tat- 
Beclin-1 groups compared to the control group. 
However, treatment with corilagin significantly (p 
< 0.01) decreased the volume of infarcted tissue 
compared with that of the MCAO group.  




Figure 1: Effect of corilagin on neurological defect in cerebral ischemic rats. Mean ± SD (n = 10); ** p < 0.01 Vs 
control; # p < 0.05, ## p < 0.01 vs MCAO, @ p < 0.05; @@ p < 0.01 vs Tat-Beclin-1 
 
Moreover, the percentage of infarct volume was 
increased in the corilagin+tat-Beclin-1-treated 
group compared with the corilagin-treated group. 
 
Effect of corilagin on infarct volume 
 
The effect of corilagin on the infarct volume was 
determined by TTC staining as shown in Figure 
2. Treatment with corilagin decreased the size of 
infarcted tissue compared to that of the MCAO 
group. There was a significant increase in the 
volume of infarcted tissue in the MCAO and Tat- 
Beclin-1 groups compared to the control group. 
However, treatment with corilagin significantly (p 
< 0.01) decreased the volume of infarcted tissue 
compared with that of the MCAO group. 
Moreover, the percentage of infarct volume was 
increased in the corilagin+tat-Beclin-1-treated 





Figure 2: Effect of corilagin on volume of infarcted brain tissues in cerebral ischemic rats. Mean ± SD (n = 10); ** 
p < 0.01 vs control; # p < 0.05, ## p < 0.01 vs MCAO and @ p < 0.05, @@ p < 0.01 vs Tat-Beclin-1 
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Effects of corilagin on cerebral oedema 
 
Figure 3 shows that that there was significant (p 
< 0.01) increase in the water content of the 
cerebral tissues in MCAO and Tat-Beclin-1 
groups compared with that of the control group. 
However, treatment with corilagin significantly (p 
< 0.01) decreased the water content in the 
cerebral tissues of the ischaemic rats compared 
with the MACO group. Moreover, the water 
content in the cerebral tissue was increased in 
the corilagin + tat-Beclin-1-treated group 
compared with the corilagin-treated group. 
 
 
Effect of corilagin on autophagic activity 
 
The effects of corilagin on the level of autophagy 
were estimated by western blotting of the 
cerebral tissues from the cerebral ischaemic rats 
as shown in Figure 4. Treatment with corilagin 
significantly decreased the expression level of 
LC3-II in cerebral tissues of cerebral ischaemic 
rats compared with the MCAO group. However, 
the LC3-II/LC3-I ratio also decreased in cerebral 
ischaemic tissues compared with the MCAO 
group. The LC3-II and LC3-II/LC3-I ratio in the 
cerebral tissues increased in the corilagin+tat-
Beclin-1-treated group compared with the 
corilagin-treated group. 
 
Figure 3: Effect of corilagin on water content in the brain tissues of cerebral ischemic rats. Mean ± SD (n = 10); 
** p < 0.01 vs control; # p < 0.05, ## p < 0.01 vs MCAO and @ p < 0.05, @@ p < 0.01 vs Tat-Beclin-1 
 
                                                
  
    (B)        (C) 
Figure 4: Effect of corilagin on autophagy of cerebral tissues in cerebral ischemic rats. A. Western blot result, B. 
Expression of LC3-II, C. Ratio of LC3-II/LC3-I; Mean ± SD (n = 10); ** p < 0.01 Vs control; # p < 0.05, ## p < 0.01 
Vs MCAO and @ p < 0.05, @@ p < 0.01 Vs Tat-Beclin-1 




Figure 5: Effect of corilagin on the level of LC3 mRNA in cerebral ischemic rats by real time PCR. Mean ± SD (n 
= 10); ** p < 0.01 vs control; # p < 0.05, ## p < 0.01 vs MCAO and @ p < 0.05, @@ p < 0.01 Vs Tat-Beclin-
Effects of corilagin on the level of LC3 mRNA 
 
The effect of corilagin on autophagy was 
assessed by measuring the level of LC3 mRNA 
using real time PCR as shown in Figure 5. In 
cerebral ischaemia, the level of LC3 mRNA was 
significantly enhanced (p < 0.01) in the MCAO 
and Tat-Beclin-1 groups, compared to the control 
group. 
 
Treatment with corilagin significantly reduced the 
level of LC3 mRNA in cerebral infarcted tissues 
compared with the MCAO group. Moreover, the 
level of LC3 mRNA in the cerebral tissue was 
increased in the corilagin+tat-Beclin-1-treated 
group compared with the corilagin-treated group. 
 
Effect of corilagin on autophagy in neurons 
and astrocytes 
 
The effect of corilagin on autophagy in brain 
tissues of cerebral ischaemic rats were 
determined by using antibodies against NeuN, 
GFAP, and LC3, and immunofluorescence as 
shown in Figure 6. There were significant 
increases in the percentages of LC3-II positive 
neurons in cerebral ischaemic tissues in the 
MCAO and Tat-Beclin-1 groups compared to the 
control group. Treatment with corilagin 
significantly decreased the percentage of LC3-II 
positive neurons compared to cerebral tissues 
from the MCAO- and Tat-Beclin-1-treated 
groups. However, the percentage of LC3-II 
positive astrocytes was significantly reduced in 
the corlagin-treated group compared to the 
MCAO group. Moreover, the percentage of LC3-
II positive astrocytes in the cerebral tissue was 
increased in the corilagin+tat-Beclin-1-treated 





Neuronal injury induced by cerebral ischaemia 
causes necrosis, apoptosis, and autophagy [18]. 
Autophagy was reported to provide a protective 
role for the survival of neurons, but excessive 
autophagy can result in cell death. Excessive 
autophagic activity during cerebral ischaemia 
also results in cell death. Studies have 
suggested that reversing autophagy can provide 
neuroprotection [19]. Thus, in this study, the 
neuroprotective effects of corlagin were 
assessed during cerebral ischaemia. Treatment 
with corlagin significantly decreased the 
neurological deficit score, infarct volume, and 
water content in the cerebral tissues of cerebral 
ischaemia rats compared to the MCOA and Tat-
Beclin-1-treated groups. In yeast, after post-
translational modification, LC3 is present in the 
autophagosomal membranes [20]. Studies have 
shown that autophagosome formation was 
confirmed by the conversion of LC3-I to LC3-II, 
which is formed during autophagy. Antibodies 
against LC3 have been used to estimate the 
autophagy-related formation of LC3-I and LC3-II 
[21-23]. However, the ratio of LC3I/LC3II also 
represents the degree of autophagy. Thus, in the 
present study, the effects of corlagin were 
assessed on the expressions of LCI and LC3II to 
estimate the extent of autophagy. Treatment with 
corlagin significantly attenuated the expressions 
of LCI and LC3II, and the ratio of LCI/LCII in the 
cerebral tissues of cerebral ischaemic rats. 
 
In this investigation, the activation of autophagy 
was assessed after including an inducer on the 
3rd and 6th days of treatment. Tat-Beclin-1 was 
reported to react with beclin-1 to initiate 
autophagy. The specific effects of corlagin on 




      (A) 
 
(B) 





Figure 7: Effect of corilagin on the percentage of LC3-II positive neurons and astrocytes Mean ± SD (n=10); **p 
< 0.01 vs control; #p < 0.05, ##p < 0.01 vs MCAO and @p<0.05, @@p < 0.01 vs Tat-Beclin-1 
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autophagy were estimated by co-administering 
tat-Beclin-1. The effects of corlagin were 
abolished by administering tat-Beclin-1 to a 
group of rats. Thus, in cerebral ischaemic rats, 





Corlagin attenuates the neuronal damage by 
decreasing the autophagy in cerebral tissue, thus 
suggesting that corlagin has potentials to be use 
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